In a 68-year-old man with metastatic lung cancer on scheduled morphine who now reports tingling and burning in his leg, what pain pathway is most likely involved and which adjuvant medication (e.g., gabapentin, duloxetine) is appropriate?

Neuropathic Pain Pathway and Treatment with Gabapentin

This patient is experiencing neuropathic pain, characterized by the tingling and burning sensations in his legs, and gabapentin is the most appropriate first-line adjuvant therapy to add to his opioid regimen.

Pain Pathway Classification

The symptoms of tingling and burning are classic descriptors of neuropathic pain, which results from damage or dysfunction in the nervous system rather than ongoing tissue damage 1. This is distinct from the throbbing abdominal pain (likely nociceptive), indicating this patient has mixed pain mechanisms requiring different therapeutic approaches.

Why Gabapentin is the Optimal Choice

Gabapentin is a first-line coanalgesic for cancer-related neuropathic pain and should be added to his morphine regimen 1. The NCCN guidelines explicitly state that anticonvulsants and antidepressants are first-line coanalgesics for neuropathic cancer pain that is only partially responsive to opioids 1.

Gabapentin Dosing Strategy:

• Start: 100-300 mg at bedtime (given his age of 68, use slower titration for elderly patients) 1
• Titrate: Increase by 50-100% every few days to 900-3600 mg daily in divided doses (2-3 times daily) 1
• Target: Continue increasing until analgesic effect achieved, side effects become unmanageable, or maximum dose reached 1
• Important: No renal dose adjustment needed since he has normal renal function 1

Why Not Duloxetine or Acetaminophen?

Duloxetine Limitations:

While duloxetine is also a first-line option for neuropathic pain 1, it has significant disadvantages in this specific patient:

• Constipation risk: The FDA label warns of anticholinergic effects including constipation 2, and this patient already has severe constipation (last bowel movement 5 days ago, likely opioid-induced)
• Urinary retention risk: FDA warnings about urinary hesitation/retention 2 are concerning in elderly males
• Dosing: 30-60 mg daily, increasing to 60-120 mg daily 1

Acetaminophen:

Acetaminophen is not indicated for neuropathic pain - it has no efficacy for nerve-related pain mechanisms and would not address the tingling/burning symptoms. It may help the throbbing abdominal pain component but is not the priority given the new neuropathic symptoms.

Critical Additional Considerations

Address the Constipation Emergency:

The 5-day absence of bowel movements is a medical emergency requiring immediate intervention before it worsens with gabapentin (which can cause constipation, though less than duloxetine). The morphine is clearly causing severe constipation, and prophylactic laxatives should have been started 3.

Optimize the Opioid Regimen:

His current morphine dosing (10 mg every 4 hours = 60 mg/day) is inadequate given pain scores of 8-10/10. According to guidelines 3:

• Provide rescue doses of immediate-release morphine (same as regular dose, can be given hourly if needed)
• Review total daily morphine use and adjust regular dosing upward
• Consider switching to modified-release formulation once pain is controlled

Trial-and-Error Approach:

Educate the patient that coanalgesic therapy requires patience 1. Response to gabapentin varies among individuals, and if inadequate response occurs after reaching therapeutic doses, switching to duloxetine or pregabalin may be necessary.

Common Pitfalls to Avoid

1. Don't delay gabapentin initiation waiting for constipation resolution - start both interventions simultaneously
2. Don't undertitrate - many clinicians stop at subtherapeutic doses; push to 1800-3600 mg/day if tolerated
3. Don't abandon opioid optimization - neuropathic pain requires combination therapy, not opioid replacement 1
4. Monitor for sedation when combining gabapentin with opioids, especially during titration 4, 5